OR13-02 Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss

Purpose: Treatment with denosumab (DMAB) decreases bone resorption and fracture risk. Following discontinuation, bone resorption increases, bone mass is lost and fractures have been reported. The aim of the study was to investigate if an infusion of zoledronic acid (ZOL) can prevent increases in bon...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Endocr Soc
Hlavní autoři: Sølling, Anne Sophie K, Harsløf, Torben, Langdahl, Bente Lomholt
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Bone and Mineral Metabolism
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7207527/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.1217
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky